Erica Whittaker

Erica Whittaker is an accomplished executive with extensive experience in the biotechnology and pharmaceutical industries. Currently serving as the VP and Head of the Corporate Venture Fund at UCB since November 2010, Erica holds several board director positions for companies including StrideBio, Inc., Rinri Therapeutics, and Ally Therapeutics. Erica previously worked as VP of Market Access & Pricing for Europe at UCB and as VP of Strategy & Partnering for NewMedicines. Prior to UCB, Erica offered consultancy services through Whittaker BioPharma Consultancy and excelled as a Senior Equity Analyst at Merrill Lynch, where recognition as one of the top European biotechnology analysts was achieved. Beginning a career in business development at PPL Therapeutics, Erica oversaw the licensing of the groundbreaking "Dolly the Sheep" technology. Erica holds a B.A. in Biology and Comparative Literature from Brown University, an MBA from Heriot-Watt University, and a PhD in Molecular Biochemistry from the University of Edinburgh.